Abstract
IntroductionLiraglutide is a glucagon-like peptide-1 analogue used to treat type 2 diabetes mellitus (T2DM). To date, limited long-term data (> 2 years) exist comparing real-world diabetes-related effectiveness and costs for liraglutide versus insulin treatment.MethodsThis retrospective claims data analysis covered the period from 1 January 2010 to 31 December 2017 and included continuously insured patients with T2DM who initiated insulin or liraglutide and had 3.5 or 5 years’ follow-up data, identified using the German AOK PLUS dataset. Propensity score matching (PSM) was used to adjust for patient characteristics.ResultsAfter PSM, there were 825 and 436 patients in the liraglutide and insulin groups at 3.5 and 5 years’ follow-up, respectively. Baseline characteristics were similar between compared cohorts. The respective change from baseline to follow-up in mean glycated haemoglobin for liraglutide and insulin patients was − 0.88% and − 0.81% (p > 0.100) after 3.5 years and − 1.15%/ − 1.02% (p > 0.100) after 5 years. Mean respective changes in body mass index (kg/m2) were − 1.21/+ 1.14 (p < 0.001) after 3.5 years and − 1.29/+ 1.13 after 5 years (p < 0.001). Liraglutide- versus insulin-treated patients were less likely to have an early T2DM-related hospitalisation (3.5-year hazard ratio [HR]: 0.414 [95% confidence interval (CI) 0.263–0.651]; 5-year HR: 0.448 [95% CI 0.286–0.701]). At 5 years’ follow-up, there was no statistically significant difference in total direct costs between treatment groups (cost ratio: 1.069 [95% CI 0.98–1.13]; p > 0.100).ConclusionThe clinical effectiveness of liraglutide is maintained long term (up to 5 years). Liraglutide treatment is not associated with higher total direct healthcare costs.Electronic Supplementary MaterialThe online version of this article (10.1007/s13300-020-00903-0) contains supplementary material, which is available to authorized users.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
